Mitchell Brigell
Directeur Technique/Scientifique/R&D chez OCUPHIRE PHARMA, INC.
Profil
Mitchell Brigell is currently the Vice President-Clinical Development at Aerpio Therapeutics, Inc. and the Head-Clinical Development & Strategy at Ocuphire Pharma, Inc. Previously, he held the position of Executive Director-Translational Medicine at Novartis Institutes of Biomedical Research from 2007 to 2013 and Vice President-Clinical Development at Aerpio Pharmaceuticals, Inc. from 2013 to 2019.
He also served as the Vice President-Americas Region at ISCEV.
Dr. Brigell holds a doctorate degree from Kansas State University.
Postes actifs de Mitchell Brigell
| Sociétés | Poste | Début |
|---|---|---|
| OCUPHIRE PHARMA, INC. | Directeur Technique/Scientifique/R&D | - |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Mitchell Brigell
| Sociétés | Poste | Fin |
|---|---|---|
| AERPIO PHARMACEUTICALS | Directeur Technique/Scientifique/R&D | 01/01/2019 |
Novartis Institutes of Biomedical Research
 Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Corporate Officer/Principal | 01/08/2013 |
| ISCEV | Corporate Officer/Principal | - |
Formation de Mitchell Brigell
| Kansas State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OCUPHIRE PHARMA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Novartis Institutes of Biomedical Research
Novartis Institutes of Biomedical Research BiotechnologyHealth Technology Novartis Institutes of Biomedical Research operates a pharmaceutical research organization. The private company is based in Emeryville. | Health Technology |
| ISCEV |
